EP3463398A4 - IMMUNE CONTROL POINT INHIBITORS AND CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF CANCER - Google Patents

IMMUNE CONTROL POINT INHIBITORS AND CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF CANCER Download PDF

Info

Publication number
EP3463398A4
EP3463398A4 EP17802270.3A EP17802270A EP3463398A4 EP 3463398 A4 EP3463398 A4 EP 3463398A4 EP 17802270 A EP17802270 A EP 17802270A EP 3463398 A4 EP3463398 A4 EP 3463398A4
Authority
EP
European Patent Office
Prior art keywords
cytotoxic
cells
treating cancer
checkpoint inhibitors
immunity checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17802270.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3463398A1 (en
Inventor
Rajiv Khanna
Corey Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of EP3463398A1 publication Critical patent/EP3463398A1/en
Publication of EP3463398A4 publication Critical patent/EP3463398A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP17802270.3A 2016-05-25 2017-05-25 IMMUNE CONTROL POINT INHIBITORS AND CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF CANCER Withdrawn EP3463398A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341402P 2016-05-25 2016-05-25
PCT/IB2017/000740 WO2017203362A1 (en) 2016-05-25 2017-05-25 Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer

Publications (2)

Publication Number Publication Date
EP3463398A1 EP3463398A1 (en) 2019-04-10
EP3463398A4 true EP3463398A4 (en) 2020-03-11

Family

ID=60411124

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17802270.3A Withdrawn EP3463398A4 (en) 2016-05-25 2017-05-25 IMMUNE CONTROL POINT INHIBITORS AND CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF CANCER

Country Status (9)

Country Link
EP (1) EP3463398A4 (enExample)
JP (1) JP2019516768A (enExample)
KR (1) KR20190028664A (enExample)
CN (1) CN109496155A (enExample)
AR (1) AR108624A1 (enExample)
AU (1) AU2017271128A1 (enExample)
CA (1) CA3023845A1 (enExample)
SG (1) SG11201809541UA (enExample)
WO (1) WO2017203362A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3666888A4 (en) * 2017-08-10 2021-09-01 Good T Cells, Inc. T-CELL ACTIVATION METHOD FOR CANCER TREATMENT
WO2020227279A1 (en) * 2019-05-06 2020-11-12 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
CN110452870A (zh) * 2019-05-20 2019-11-15 河南省肿瘤医院 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品
CA3146845A1 (en) * 2019-07-15 2021-01-21 Neogene Therapeutics B.V. Method to isolate tcr genes
US20230210984A1 (en) * 2019-10-23 2023-07-06 The Council Of The Queensland Institute Of Medical Research Adoptive immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016070136A1 (en) * 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086083A2 (en) * 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
NZ600281A (en) * 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
US8883500B2 (en) * 2008-12-05 2014-11-11 Northeastern University Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
BR112014014591A8 (pt) * 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
JP6368308B2 (ja) * 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
JP2016540042A (ja) * 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
EP3154350B1 (en) * 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
US10987412B2 (en) * 2014-09-17 2021-04-27 The John Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016070136A1 (en) * 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Delivery of biomolecules to immune cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Current topics in microbiology and immunology", vol. 391, 1 January 2015, SPRINGER BERLIN HEIDELBERG, Berlin, Heidelberg, ISBN: 978-3-540-92165-3, ISSN: 0070-217X, article STEPHEN GOTTSCHALK ET AL: "Adoptive T-Cell Immunotherapy", pages: 427 - 454, XP055286103, DOI: 10.1007/978-3-319-22834-1_15 *
BOLLARD C M ET AL: "Immunotherapy targeting EBV-expressing lymphoproliferative diseases", BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 3, 1 September 2008 (2008-09-01), pages 405 - 420, XP025404482, ISSN: 1521-6926, [retrieved on 20080912], DOI: 10.1016/J.BEHA.2008.06.002 *
CHUA MELVIN L K ET AL: "Nasopharyngeal carcinoma", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 387, no. 10022, 28 August 2015 (2015-08-28), pages 1012 - 1024, XP029453150, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(15)00055-0 *
P. COMOLI ET AL: "Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 35, 10 December 2005 (2005-12-10), pages 8942 - 8949, XP055075807, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.02.6195 *
See also references of WO2017203362A1 *

Also Published As

Publication number Publication date
WO2017203362A1 (en) 2017-11-30
JP2019516768A (ja) 2019-06-20
CA3023845A1 (en) 2017-11-30
AU2017271128A1 (en) 2019-01-03
SG11201809541UA (en) 2018-12-28
KR20190028664A (ko) 2019-03-19
CN109496155A (zh) 2019-03-19
AR108624A1 (es) 2018-09-12
EP3463398A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
EP3507304C0 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DUOCARS
EP3532464A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
EP3494142A4 (en) ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER
EP3541587C0 (en) EQUIPMENT FOR PROCESSING OBJECTS
EP3481431A4 (en) CRISPR / CAS9 COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3576781A4 (en) NEOANTIGENS AND THEIR USES IN CANCER TREATMENT
EP4067347C0 (en) HETEROCYCLIC CBP/EP300 INHIBITORS FOR THE TREATMENT OF CANCER
EP3845557C0 (en) METHOD FOR TREATING CANCER USING GENETICALLY MODIFIED T CELLS
EP3416661A4 (en) COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
EP3474879A4 (en) Compositions and methods of treating melanoma
EP3697426C0 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD22 IMMUNOTHERAPY
EP3355926A4 (en) Method for treating cancer using a combination of dna damaging agents and atr inhibitors
EP3458158A4 (en) COMPOSITIONS AND METHODS FOR TREATING ECZEMA
EP3506944A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR SUPPRESSOR CANCER
EP3507360A4 (en) COMPOSITIONS AND TREATMENT METHODS FOR TUMOR SUPPRESSOR-DEFICIENT CANCER
EP3452170A4 (en) DRY POWDER OF TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION
EP3474849A4 (en) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF DIABETES
EP3565898A4 (en) CAR-VEGFR-2 IMMUNE CELLS FOR CANCER TREATMENT
EP3484913C0 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL251759B (en) Compositions and methods for treating insomnia
EP3452028A4 (en) COMPOSITIONS AND METHOD FOR TREATING ACID-BASED DISORDERS
EP3519487A4 (en) REACTOR FOR PROCESSING POLYSTYRENE MATERIAL
EP3154701C0 (de) Mahlanlage und verfahren zur zerkleinerung von mahlgut
EP3558329A4 (en) COMPOSITIONS AND PROCEDURES FOR INHIBITING EPILEPSY SEIZURES
EP3541421A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181225

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200206

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/00 20060101ALI20200131BHEP

Ipc: C07K 16/28 20060101ALI20200131BHEP

Ipc: A61K 45/06 20060101ALI20200131BHEP

Ipc: C12N 5/0783 20100101ALI20200131BHEP

Ipc: A61P 35/00 20060101ALI20200131BHEP

Ipc: A61K 39/395 20060101ALI20200131BHEP

Ipc: A61K 35/17 20150101AFI20200131BHEP

Ipc: A61K 38/17 20060101ALI20200131BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20200902